BTX - BioTime, Inc.

NYSE American - Nasdaq Real-time price. Currency in USD
2.58
+0.01 (+0.39%)
As of 3:28PM EST. Market open.
Stock chart is not supported by your current browser
Previous close2.57
Open2.54
Bid2.58 x 700
Ask2.59 x 1100
Day's range2.53 - 2.61
52-week range2.19 - 3.97
Volume213,787
Avg. volume350,410
Market cap327.314M
Beta1.70
PE ratio (TTM)4.34
EPS (TTM)0.60
Earnings date1 Nov 2017 - 6 Nov 2017
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est6.17
Trade prices are not sourced from all markets
  • Business Wire7 days ago

    BioTime Presents Updated OpRegen® Phase I/IIa Trial Data at AAO

    BioTime, Inc. , a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced that an abstract related to one of its lead programs, OpRegen® for dry-AMD, was presented at the annual American Academy of Ophthalmology in New Orleans, Louisiana, on November 14, 2017.

  • Business Wire9 days ago

    BioTime to Participate in Upcoming Conferences

    BioTime, Inc. , a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced

  • Associated Press13 days ago

    BioTime beats 3Q profit forecasts

    On a per-share basis, the Alameda, California-based company said it had profit of 12 cents. Losses, adjusted for non-recurring gains, were 5 cents per share. The results topped Wall Street expectations. ...

  • Business Wire13 days ago

    BioTime Reports Third Quarter Results and Recent Corporate Accomplishments

    BioTime, Inc. , a late stage clinical biotechnology company developing and commercializing products addressing degenerative diseases, today reported financial results for the third quarter ended September 30, 2017.

  • Business Wire14 days ago

    AgeX Therapeutics VP of New Technology Discovery Aubrey de Grey to Serve on Aging & Longevity Panel at FT Global Pharmaceutical and Biotechnology Conference, November 9-10 in London

    AgeX Therapeutics, Inc. , a subsidiary of BioTime, Inc. announced today that VP of New Scientific Discovery Aubrey de Grey, Ph.D. is participating on a panel at the FT Global Pharmaceutical and Biotechnology Conference, November 9-10 in London.

  • Business Wire14 days ago

    AgeX Therapeutics VP of New Technology Discovery Aubrey de Grey to Serve on Aging & Longevity Panel at FT Global Pharmaceutical and Biotechnology Conference, November 9-10 in London

    “A growing sum of company and investment capital is making its way into the study of aging with the aim not only of extending healthspan - but also of studying the link between the processes of aging with a view to halting the onset of and the many diseases which afflict old age to include Alzheimer's, heart disease and chronic diseases such as diabetes. What lies ahead could be a future in which aging could be viewed as just another disease to be ‘cured’, resulting in a less crippling and costly burden from age-related drug development and for care within the healthcare system. AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE American: BTX), is a biotechnology company applying technology relating to cellular immortality and regenerative biology to aging and age-related diseases.

  • Business Wire21 days ago

    BioTime to Participate in the Jefferies 2017 London Healthcare Conference

    ALAMEDA, Calif.--(BUSINESSWIRE)-- BioTime, Inc. (NYSE American: BTX), a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases, today ...

  • Business Wire21 days ago

    BioTime to Participate in the Jefferies 2017 London Healthcare Conference

    BioTime, Inc. , a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced that Adi Mohanty, Co-Chief Executive Officer, and Russell Skibsted, Chief Financial Officer, will participate in the Jefferies 2017 London Healthcare Conference on November 15th and 16th, in London, United Kingdom.

  • Business Wirelast month

    BioTime, Inc. Announces Pricing of $25.0 Million Public Offering of Common Stock

    BioTime, Inc. , a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced the pricing of an underwritten public offering of 9,615,385 shares of its common stock at a public offering price of $2.60 per share.

  • Business Wirelast month

    BioTime, Inc. Announces Proposed Public Offering of Common Stock

    BioTime, Inc. , a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced its intent to offer to sell shares of its common stock in an underwritten public offering.

  • Business Wirelast month

    BioTime Announces First Patient in U.S. Clinical Trial Treated for Facial Volume Deficit

    BioTime, Inc. , a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases, today reported that an investigator-led clinical trial has successfully treated its first patient in a study of Premvia™ as a carrier for stromal vascular fraction cells for the treatment of age-related volume loss in the face.

  • Business Wirelast month

    BioTime and Processa Announce Their Intention to Enter into a HyStem® Sublicense for Drug Delivery

    BioTime, Inc. , a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases, today reached agreement on terms to sublicense certain HyStem® rights to Processa Pharmaceuticals, Inc.

  • Business Wire2 months ago

    BioTime to Present at the Cell and Gene Meeting on the Mesa

    BioTime, Inc. , a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced that Jim Knight, SVP, Head of Corporate Development, will present at the Cell & Gene Therapy Meeting on the Mesa.

  • Business Wire5 months ago

    BioTime’s Renevia® Achieves Primary Endpoint in European Pivotal Trial

    BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today reported that, based on the analysis of top line data, the Renevia® pivotal trial in Europe has met its primary endpoint. The primary endpoint was the change in hemifacial volume at six months in the treated patients compared to patients in the delayed treatment arm as measured by 3D photographic volumetric assessment. Untreated patients had no incremental hemifacial volume after six months.

  • Business Wire5 months ago

    BioTime to Announce Top Line Data From the Company’s Renevia European Pivotal trial

    BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that it will report the top line data from the Company’s Renevia European pivotal trial, before the US market open on Wednesday, June 14, 2017. The Company will host a conference call and webcast the same day at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time to discuss the results.

  • Business Wire7 months ago

    BioTime Co-CEO Dr. Michael D. West to Present at World Advanced Therapies & Regenerative Medicine Congress on May 17 and 19

    ALAMEDA, Calif.--(BUSINESSWIRE)-- Dr. West to Deliver Presentation on Applying AI to Stem Cell Biology and Participate in Roundtable Discussion BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology ...

  • Business Wire8 months ago

    Key BioTime Patents Upheld by European Patent Office

    BioTime, Inc. (NYSE MKT:BTX), a clinical stage biotechnology company developing and commercializing products addressing degenerative disease, today announced the successful defense of two key patents from challenge before the European Patent Office (EPO) Opposition division. A large pharmaceutical company and an anonymous filer challenged the EPO’s previous grant of two European patents (EP2554661 and EP2147094), which cover the proprietary directed differentiation methods to produce pluripotent stem cell-derived cell replacement therapies being developed to treat retinal degenerative diseases such as age-related macular degeneration (“AMD”).

  • Business Wire11 months ago

    BioTime Achieves Patient Recruitment Milestone in Renevia Pivotal Trial

    BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, announced that it has achieved an important patient enrollment milestone in its Renevia® pivotal trial in Europe. “We are pleased with the progress in our Renevia pivotal trial,” commented Adi Mohanty, Co-Chief Executive Officer of BioTime.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes